drugset / Trial / NCT06040372
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
Timeline
- Start
- 2020-03-16
- Primary completion
- 2022-03-30
- Completion
- 2022-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB54640 | Unknown | 10 mg | — |
| Subject | LB54640 | Unknown | 25 mg | — |
| Subject | LB54640 | Unknown | 50 mg | — |
| Subject | LB54640 | Unknown | 100 mg | — |
| Subject | LB54640 | Unknown | 200 mg | — |
| Subject | LB54640 | Unknown | 400 mg | — |
| Subject | LB54640 | Unknown | 600 mg | — |